Chordoma Disease Therapeutics Market, by Drug Class (Antimetabolites, Anthracycline, VEGFR Inhibitors, EGFR Inhibitor, and Others), by Treatment Type (Chemotherapy, Targeted Therapy, Radiation Therapy, and Others), by End User (Hospitals, Clinics, Oncolog

Chordoma Disease Therapeutics Market, by Drug Class (Antimetabolites, Anthracycline, VEGFR Inhibitors, EGFR Inhibitor, and Others), by Treatment Type (Chemotherapy, Targeted Therapy, Radiation Therapy, and Others), by End User (Hospitals, Clinics, Oncology Centers, and Others), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028

Chordoma is a rare cancer along with many treatment limitations. The tumor grows slowly in the bones of skull and spine when an individual is suffering from chordoma. Around half of all chordomas occur at the sacrum (base of the spine), approximately one third occur in the occiput (base of the skull), while rest of the chordomas occur in the cervical (neck), thoracic (upper back) or lumbar (lower back) vertebrae of the spine. A chordoma growth in the spine region may cause weakness, pain or numbness in the back, legs or arms. An occipital chordoma (chordoma at the base of skull) may lead to diplopia (double vision) and headaches while coccygeal chordoma (chordoma occurring in the tailbone) may result in a large lump, which may cause problems with bladder or bowel function.
Although chordoma is a rare type of cancer, increasing research and development activities for its treatment is likely to drive growth of the chordoma disease therapeutics market over the forecast period.
Market Dynamics
The increasing number of research and development activities by key players operating in the market, in order to develop advanced treatment for chordoma, is expected to propel the market growth over the forecast period. For instance, in June 2018, Boehringer Ingelheim, a pharmaceutical company, initiated phase 2 clinical trial in collaboration with the Chordoma Foundation, a non-profit organization. The purpose of the trial was to evaluate the safety and efficacy of Afatinib, a tyrosine kinase inhibitor, as first line or later line treatment in advanced chordoma.
Key features of the study:
This report provides in-depth analysis of the global chordoma disease therapeutics market, and provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2022-2028), considering 2021 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new drug launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global chordoma disease therapeutics market based on the following parameters – company overview, financial performance, Drugs portfolio, market presence, distribution strategies, key developments, strategies, and future plans
Key companies covered as a part of this study include GlaxoSmithKline Plc, Bavarian Nordic A/S, Boehringer Ingelheim International GmbH, Pfizer, Inc., Merck & Co., Inc., Sanofi SA, Astellas Pharma Inc., AstraZeneca plc, Amgen, Inc., Bristol-Myers Squibb and Company, Novartis International AG, Bayer AG, Dr. Reddy’s Laboratories Ltd., and Mylan N.V.
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future drug launches, drug class up-gradation, market expansion, and marketing tactics
The global chordoma disease therapeutics market report caters to various stakeholders in this industry including investors, suppliers, drugs manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global chordoma disease therapeutics market
Detailed Segmentation:
Global Chordoma Disease Therapeutics Market, By Drug Class:
Antimetabolites
Anthracycline
VEGFR Inhibitors
EGFR Inhibitor
Others
Global Chordoma Disease Therapeutics Market, By Treatment Type:
Chemotherapy
Targeted Therapy
Radiation Therapy
Others
Global Chordoma Disease Therapeutics Market, By End User:
Hospitals
Clinics
Oncology Centers
Others
Global Chordoma Disease Therapeutics Market, By Region:
North America
By Drug Class:
Antimetabolites
Anthracycline
VEGFR Inhibitors
EGFR Inhibitor
Others
By Treatment Type
Chemotherapy
Targeted Therapy
Radiation Therapy
Others
By End User:
Hospitals
Clinics
Oncology Centers
Others
By Country:
U.S.
Canada
Latin America
By Drug Class:
Antimetabolites
Anthracycline
VEGFR Inhibitors
EGFR Inhibitor
Others
By Treatment Type
Chemotherapy
Targeted Therapy
Radiation Therapy
Others
By End User:
Hospitals
Clinics
Oncology Centers
Others
By Country:
Brazil
Mexico
Argentina
Rest of Latin America
Europe
By Drug Class:
Antimetabolites
Anthracycline
VEGFR Inhibitors
EGFR Inhibitor
Others
By Treatment Type
Chemotherapy
Targeted Therapy
Radiation Therapy
Others
By End User:
Hospitals
Clinics
Oncology Centers
Others
By Country:
Germany
U.K.
France
Italy
Spain
Russia
Rest of Europe
Asia Pacific
By Drug Class:
Antimetabolites
Anthracycline
VEGFR Inhibitors
EGFR Inhibitor
Others
By Treatment Type
Chemotherapy
Targeted Therapy
Radiation Therapy
Others
By End User:
Hospitals
Clinics
Oncology Centers
Others
By Country:
China
India
Japan
Australia
South Korea
ASEAN
Rest of Asia Pacific
Middle East
By Drug Class:
Antimetabolites
Anthracycline
VEGFR Inhibitors
EGFR Inhibitor
Others
By Treatment Type
Chemotherapy
Targeted Therapy
Radiation Therapy
Others
By End User:
Hospitals
Clinics
Oncology Centers
Others
By Country:
GCC
Israel
Rest of Middle East
Africa
By Drug Class:
Antimetabolites
Anthracycline
VEGFR Inhibitors
EGFR Inhibitor
Others
By Treatment Type
Chemotherapy
Targeted Therapy
Radiation Therapy
Others
By End User:
Hospitals
Clinics
Oncology Centers
Others
By Country/Region:
South Africa
Central Africa
North Africa
Company Profiles
GlaxoSmithKline Plc *
Company Overview
Material Portfolio
Financial Performance
Key Highlights
Market Strategies
Bavarian Nordic A/S
Boehringer Ingelheim International GmbH
Pfizer, Inc.
Merck & Co., Inc.
Sanofi SA
Astellas Pharma Inc.
AstraZeneca plc
Amgen, Inc.
Bristol-Myers Squibb and Company
Novartis International AG
Bayer AG
Dr. Reddy’s Laboratories Ltd.
Mylan N.V.
“*” marked represents similar segmentation in other categories in the respective section.